Wrap Technologies, Inc. has appointed former New York City Police Department Deputy Commissioner Edward Delatorre Jr. to its Board of Directors, effective October 20, 2026, the company announced. Delatorre helped introduce Narcan into NYPD patrol operations, guiding the opioid-overdose antidote program from a Staten Island pilot to citywide adoption and later sharing the model with departments nationally and internationally.
The appointment matters because it pairs a public-safety executive known for turning a single tool into a sustainable agency program with a company trying to do the same for non-lethal response. Wrap Technologies, a provider of non-lethal response technologies and public safety solutions, sees a direct parallel in its own work: making Non-Lethal Response technology, training and policy a practical, repeatable capability that agencies can adopt and sustain. The company trades on Nasdaq under the ticker WRAP, and details on its business are available through its Wrap Technologies, Inc. (NASDAQ: WRAP) client page.
The Narcan example illustrates the gap between having a tool and having a program. When a police officer reaches someone in the middle of an opioid overdose, a single dose of Narcan can mean that person goes home to their family. Carrying it is now routine for many officers, but it became routine because someone did the slower work of building the program around it. For the NYPD, part of that work was led by Delatorre, whose appointment Wrap Technologies appointed to its board.
For investors and agencies watching the non-lethal technology sector, the signal is that Wrap is emphasizing deployment and sustainment rather than hardware alone. Training and policy are often the difference between a pilot that fades and a capability that sticks, and the company is framing its board addition around that operational discipline. Additional coverage of the announcement is available through Read More.
The announcement was distributed via NEWMEDIAWIRE. Statements attributed to Wrap Technologies or its management, including forward-looking statements regarding product adoption, strategy, the contributions of its Board of Directors, or market opportunities, reflect the company's views and are subject to risks and uncertainties, and actual results may differ materially. Readers should conduct their own due diligence and consult a qualified professional, and can review full terms of use and disclaimers at https://IBN.ai/Disclaimer.
